Clinical trials: Tumor Angiogenesis
Neuroendocrine Tumors, Neuroendocrine Neoplasm
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and…
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Neoplasm, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- REBORN (NCT04464122)
- Testing
- Somatostatin analog; chemotherapy
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Roma La Sapienza
Aortic Aneurysm, Abdominal, Carotid Atherosclerosis
Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation
Stroke and abdominal aortic aneurysms (AAAs) are common and highly lethal vascular diseases. Angiogenesis and infiltration of inflammatory cells such as macrophages may cause stroke and AAAs.
- Trial name
- NCT02995642
- Testing
- 18F-FPPRGD2, Positron emission tomography, Computed tomography
- Where
- United States
- Sponsor
- Stanford University
Systemic Sclerosis
Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
We propose to examine several angiogenic/angiostatic mediators in the skin and serum of subjects with SSc and compare it to levels found in the skin and serum of healthy subjects.
- Trial name
- NCT00668473
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Non-small Cell Lung Cancer
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of this study is to examine the safety of volociximab in combination with a standard treatment of carboplatin and paclitaxel in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV)…
- Trial name
- NCT00654758
- Testing
- M200 (Volociximab), Carboplatin, Paclitaxel
- Volunteers
- 33 people
- Sponsor
- AbbVie
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases
- Trial name
- NCT01009593
- Testing
- ABT-869, Sorafenib
- Where
- 163 sites in United States, Argentina and 27 more
- Volunteers
- 1,035 people
- Sponsor
- Abbott
Prostate Cancer
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
This multi-center study will evaluate whether thalidomide can improve the effectiveness of the drugs leuprolide or goserelin in treating testosterone-dependent prostate cancer.
- Trial name
- NCT00004635
- Testing
- Thalidomide, leuprolide acetate, goserelin
- Where
- 9 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
This study aimed to evaluate the efficacy and safety of first-line Toripalimab combined with bevacizumab, nab-paclitaxel and carboplatin in the treatment of patients with advanced pulmonary sarcomatoid carcinoma.
- Conditions
- Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases, Thoracic Neoplasms
- Trial name
- NCT04725448
- Testing
- Toripalimab, Bevacizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Glioblastoma
Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma
In this pilot study, the study evaluators will evaluate the ability of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG PET) and the computed tomography (CT) perfusion scanner, individually and combined, to…
- Trial name
- EVA DOPA (NCT04566185)
- Testing
- FDG PET, CT scan, Magnetic resonance imaging (MRI)
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Central Nervous System Embryonal Neoplasm
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to learn more about genes involved in the development of central nervous…
- Trial name
- NCT00010114
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Pediatric Brain Tumor Consortium
Endometrial Cancer
The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients
Adenocarcinoma of the endometrium is the fourth most frequent cancer in women. Surgery is the treatment of choice in patients with noninvasive or locally advanced disease.
- Trial name
- NCT00166985
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Advanced Solid Tumors, Non Small Cell Lung Cancer
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere).
- Trial name
- NCT00712504
- Testing
- sunitinib, docetaxel
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Neurofibromatosis 2
PTC299 for Treatment of Neurofibromatosis Type 2
Formation of new blood vessels (angiogenesis) is important for tumor growth in neurofibromatosis type 2 (NF2). It is known that tumors make a protein called vascular endothelial growth factor (VEGF) and there are higher levels of…
- Trial name
- NCT00911248
- Testing
- PTC299
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- PTC Therapeutics
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Retinopathy of Prematurity
Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)
The aim of the present study is to evaluate the safety and efficacy of propranolol 0.2% eye drops in treating preterm newborns with a precocious stage of retinopathy of prematurity (ROP).
- Trial name
- NCT02504944
- Testing
- Propranolol 0.2% eye drops
- Where
- 7 sites in Italy
- Volunteers
- 98 people
- Sponsor
- Meyer Children's Hospital IRCCS
Glaucoma, Neovascular
Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).
- Trial name
- NCT01922154
- Testing
- intravitreal ranibizumab, Trabeculectomy with mitomycinC
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Siriraj Hospital
Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
This study is a prospective, open-label, dual-arm exploratory Phase II clinical trial designed to assess the efficacy and safety of cadonilimab combined with anti-angiogenic agents in patients with dMMR/MSI-H recurrent or…
- Trial name
- NCT07003022
- Testing
- cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Solid Tumors
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Co-selective inhibition of VEGFRs and FGFR has the potential benefit of blocking the two most relevant players in tumor angiogenesis and simultaneously targeting proliferation in FGF-driven tumors.
- Trial name
- NCT01283945
- Testing
- Lucitanib
- Where
- 4 sites in France, Italy and 1 more
- Volunteers
- 134 people
- Sponsor
- Institut de Recherches Internationales Servier
Hepatocellular Carcinoma, Immune Checkpoint Inhibitors
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Nowadays, there are few second-line treatment options for advanced hepatocellular carcinoma (HCC). In order to further improve the efficacy of second-line treatment for advanced HCC, we plan to conduct a phase II clinical study…
- Conditions
- Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
- Trial name
- NCT06446154
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
RATIONALE: SU5416 may stop the growth of breast cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005822
- Testing
- doxorubicin hydrochloride, semaxanib, conventional surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Prostatic Neoplasms, Prostate Cancer
AMG 386 and Abiraterone for Advanced Prostate Cancer
Background: Advanced prostate cancer is treated with surgery or drugs that lower the levels of androgens (male hormones) in the body. However, some cancers become resistant to this treatment.
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Neoplasm, Prostate, Neoplasm,Prostatic
- Trial name
- NCT01553188
- Testing
- AMG 386, Abiraterone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)